If you have locally advanced prostate cancer, you may think surgery is no longer possible. That is not necessarily true. Your cancer has grown beyond the prostate but has not necessarily spread to distant parts of your body, so surgery may still be an option in carefully selected cases.
Robotic prostatectomy may form part of a wider treatment plan for you. Depending on your scans, surgical findings and final pathology, you may also need radiotherapy, hormone treatment or both. The decision will depend on your cancer’s extent, biology and your overall health.
What Is Locally Advanced Prostate Cancer?
Locally advanced prostate cancer means your cancer has grown beyond the prostate into nearby tissues or may have reached nearby pelvic lymph nodes, but it has not spread to distant parts of your body such as your bones. It commonly includes T3 or T4 disease and may also include N1 M0 disease, depending on the exact staging pattern.
This is different from localised cancer, which remains within your prostate, and metastatic cancer, which has spread further through your body. Your treatment plan will depend on your T stage as well as your PSA, Grade Group, MRI findings and lymph-node assessment.
Localised vs Locally Advanced vs Metastatic Prostate Cancer
| Stage | Where the cancer is | What it may mean for treatment |
| Localised prostate cancer | Cancer remains within the prostate | Options may include active surveillance, surgery or radiotherapy depending on cancer risk |
| Locally advanced prostate cancer | Cancer has grown beyond the prostate into nearby tissues or seminal vesicles but has not spread to distant organs | Surgery may still be considered in selected patients, often as part of a wider treatment plan |
| Regional lymph-node involvement | Cancer has reached nearby pelvic lymph nodes | Treatment planning becomes more complex and commonly involves radiotherapy plus systemic treatment |
| Metastatic prostate cancer | Cancer has spread to distant lymph nodes, bones or other organs | Treatment usually focuses on systemic therapies rather than removing the prostate alone |
Can You Have Robotic Surgery for Locally Advanced Prostate Cancer?
Yes, you may still be considered for robotic radical prostatectomy if your locally advanced prostate cancer appears suitable for surgical treatment. European and UK guidance recognise surgery as an option for selected men, often as part of a wider treatment plan.
Your decision will depend on your cancer stage, scans, overall health and whether the cancer can realistically be removed. For some men, surgery may be followed by radiotherapy or hormone treatment, while others may benefit more from radiotherapy combined with systemic treatment.
What Role Does Robotic Surgery Play?
Robot-assisted radical prostatectomy allows your surgeon to remove your prostate through keyhole surgery using specialised robotic instruments. The system provides magnified three-dimensional vision and precise instrument movement, which can help your surgeon work around important structures in your pelvis.
The robot does not decide how your cancer should be removed. Your surgeon controls the procedure and may need to remove tissue beyond the prostate if your cancer has spread locally. The priority is effective cancer removal while preserving surrounding structures where it is safe to do so.
Who Is Most Likely to Be Suitable for Surgery?
You may be considered for radical prostatectomy if your cancer appears removable, there is no clear evidence of distant spread and you are fit enough to undergo major surgery. European guidance includes selected cN0 patients as potential candidates, meaning your lymph nodes do not appear to contain cancer on clinical staging.
Your life expectancy and overall fitness also matter because the aim is long-term cancer control. Your age, other health conditions and the extent of cancer beyond your prostate will all be considered when deciding whether surgery is a reasonable option for you.
When Might Robotic Surgery Be Less Suitable?
Robotic surgery may be less suitable if your cancer has spread to distant parts of your body or cannot be removed safely. In these situations, removing your prostate alone may not control all the cancer, so other treatments may be more appropriate.
Your overall health also matters. Even if an operation is technically possible, serious heart, lung or other medical problems may make major surgery too risky. The key question is not simply whether surgery can be performed, but whether it is likely to give you meaningful benefit.
Why Is Accurate Staging So Important?
Accurate staging shows how far your prostate cancer has spread and whether surgery may offer meaningful cancer control. Locally advanced disease has a higher risk of lymph-node or distant spread.
MRI and PSMA PET/CT can help look for cancer beyond your prostate. Your PSA, Grade Group, scans and overall health then help your multidisciplinary team decide whether surgery is appropriate.
What Does MRI Tell Your Surgeon?
MRI can show whether your cancer has grown through the prostate capsule or into the seminal vesicles. It also helps your surgeon assess how close the tumour is to nearby structures.
These findings help guide surgical planning. If the tumour is close to a nerve bundle, your surgeon may need to remove more tissue rather than risk leaving cancer behind.
Why Might You Need PSMA PET/CT?
A PSMA PET/CT can help your doctors look for prostate cancer beyond your prostate, including in your lymph nodes, bones and other parts of your body. This is particularly useful with locally advanced cancer because the risk of disease outside the prostate is higher.
A clear scan is reassuring but cannot rule out very small areas of cancer that are too tiny to detect. Your specialist will therefore consider the PSMA PET/CT alongside your MRI, biopsy, PSA and other staging information when deciding whether robotic surgery is appropriate for you.
What Is the Difference Between cN0 and cN1 Disease?
cN0 means your scans do not show cancer in your nearby lymph nodes, while cN1 means cancer appears to have reached regional lymph nodes. Surgery may be considered for selected men with cN0 locally advanced cancer as part of a wider treatment plan.
If you have cN1 M0 disease, treatment usually involves radiotherapy to the prostate and pelvis with long-term hormone therapy, often with two years of abiraterone. Surgery is not usually the standard approach, so treatment should be planned by a specialist multidisciplinary team.
What Should Happen to Your PSA After Surgery?
After your prostate is removed, your PSA is expected to fall to an undetectable level, usually by around two months after surgery. PSA monitoring then continues over the long term. Follow-up schedules vary, but PSA is commonly checked at regular intervals during the first few years and then less frequently if it remains undetectable.
- Low PSA: An undetectable or very low PSA after surgery is reassuring.
- Persistent PSA: A detectable PSA soon after surgery may suggest that some cancer cells remain.
- Rising PSA: A later increase can indicate biochemical recurrence.
- Further treatment: Radiotherapy or hormone therapy may be considered depending on your results.
A detectable or rising PSA does not automatically mean your cancer is incurable. Your specialist will interpret the results alongside your pathology and other risk factors.
What Happens During Robotic Radical Prostatectomy?
During robotic radical prostatectomy, your surgeon removes your prostate and usually the seminal vesicles through several small abdominal openings. Your bladder is then reconnected to your urethra, and a catheter is left temporarily while the connection heals.
If your cancer has grown beyond the prostate, your surgeon may need to remove a wider area of tissue and perform pelvic lymph-node surgery. The exact approach is tailored to your cancer, with surgical planning and your surgeon’s experience playing an important role in your outcome.
Why Might Your Lymph Nodes Be Removed?
Your surgeon may remove nearby pelvic lymph nodes if there is a meaningful risk that your prostate cancer has spread to them. When lymph-node dissection is performed, current European guidance recommends an extended pelvic lymph-node dissection because it provides more accurate pathological staging. The results can help confirm your cancer stage and guide decisions about further treatment.
Lymph-node surgery can also cause complications such as lymphoceles, where lymphatic fluid collects in your pelvis. Your surgeon will therefore explain why lymph-node removal is recommended for you and how the results could affect your treatment plan.
Can You Still Have Nerve-Sparing Surgery?
Possibly, but locally advanced cancer can make nerve sparing less suitable if your tumour is close to the nerves responsible for erections. If your cancer is safely away from these structures, your surgeon may be able to preserve one or both neurovascular bundles.
Your MRI and other staging results will help guide this decision. You may have nerve sparing on both sides, one side or neither, depending on where your cancer is located. The priority is always to remove your cancer safely rather than preserve nerves when doing so could leave cancer behind.
What Will the Pathology Report Show?
After surgery, a pathologist examines your prostate and any other tissue removed. The report shows your final Grade Group, stage and whether cancer has reached the seminal vesicles or lymph nodes.
It also shows whether your surgical margins are clear. Positive margins can increase recurrence risk and may influence whether further treatment is considered.
Will You Need Radiotherapy After Surgery?
Not necessarily. If your PSA becomes undetectable and your pathology is favourable, your team may monitor you without immediate further treatment. However, features such as cancer extending beyond the prostate, a high Grade Group, positive margins, lymph-node involvement or persistent PSA may increase the chance that you will need radiotherapy.
Your specialist may recommend postoperative or early salvage radiotherapy based on your PSA and final pathology. NICE does not routinely recommend immediate radiotherapy, while European guidance may consider it for selected high-risk patients.
Might You Need Hormone Treatment as Well?
Hormone treatment, also called androgen deprivation therapy (ADT), reduces the effect of testosterone on prostate cancer. You do not automatically need ADT simply because your cancer was locally advanced and you had surgery.
You may be more likely to need it if your lymph nodes contain cancer, your PSA remains detectable after surgery or you need postoperative radiotherapy. Your final pathology and PSA results will help your team decide whether ADT would benefit you.
What Are the Long-Term Outcomes After Surgery?
Selected men with locally advanced prostate cancer can achieve long-term cancer control after radical prostatectomy. However, recurrence risk is generally higher than with lower-risk localised disease.
Your outlook depends on your Grade Group, stage, PSA, surgical margins and lymph-node findings. Some men may also need further treatment after surgery.
Evidence Note
Evidence for radical prostatectomy in locally advanced prostate cancer comes mainly from observational studies rather than randomised comparisons with modern radiotherapy. Current European guidance reports that retrospective surgical series have shown cancer-specific survival above 60% at 15 years and overall survival above 75% at ten years in selected patients, while some cT3b–T4 cohorts have reported ten-year cancer-specific survival above 87%.
These figures should not be used as personal predictions because the patients selected for surgery are often younger, fitter or have more surgically favourable disease. The important point is that radical prostatectomy can contribute to long-term cancer control in selected patients, but additional radiotherapy or systemic treatment may still be required.
How Does Surgery Compare With Radiotherapy?
Surgery is not the only potentially curative option for locally advanced prostate cancer. Radiotherapy combined with long-term hormone treatment is also a standard approach, and your specialist will consider which treatment is more suitable for your cancer and overall health.
There is no clear evidence that surgery is better than radiotherapy with hormone treatment for every man. Your decision should therefore consider both cancer control and side effects, including the potential effects on your urinary, sexual and bowel function.
UK Guidance Note
NICE recommends offering radical prostatectomy or radical radiotherapy to people with CPG 4 and 5 localised or locally advanced prostate cancer when long-term cancer control is considered achievable. If radiotherapy is chosen, NICE recommends combining radical external-beam radiotherapy with androgen deprivation therapy rather than using radiotherapy or ADT alone.
After prostatectomy, NICE does not recommend routine immediate postoperative radiotherapy or adjuvant hormone therapy outside a clinical trial, even when surgical margins are positive. Postoperative management should therefore be based on PSA follow-up, pathology and specialist multidisciplinary assessment.
How Should You Decide Whether Robotic Surgery Is Right for You?
Start by understanding what your MRI and PSMA PET/CT show about the extent of your cancer. Involvement of the capsule, seminal vesicles, nearby structures or lymph nodes can affect whether surgery is suitable.
Ask your surgeon what they expect to remove, whether nerve sparing is realistic and whether further treatment may be needed. You should also compare surgery with radiotherapy-based options before making your decision.
Myth vs Fact
| Myth | Fact |
| Locally advanced prostate cancer means surgery is impossible. | No. Radical prostatectomy can be considered in selected cN0 patients and may form part of a multimodal treatment plan. |
| A clear PSMA PET/CT proves there is no cancer in the lymph nodes. | No. PSMA PET/CT improves staging but can still miss microscopic nodal disease. |
| If lymph nodes are removed, the procedure definitely improves survival. | No. Extended pelvic lymph-node dissection improves pathological staging, but a clear survival benefit from the procedure itself has not been established. |
| A positive surgical margin means cancer was definitely left behind. | No. It means tumour reaches the edge of the removed specimen and increases recurrence risk, but it does not prove residual viable cancer remains. |
| Everyone with locally advanced cancer needs immediate radiotherapy after surgery. | No. Postoperative treatment depends on PSA, pathology and nodal findings, and UK NICE guidance does not recommend routine immediate postoperative radiotherapy solely because of adverse pathology. |
| Everyone needs hormone therapy after surgery. | No. ADT is not routinely required after prostatectomy solely because the original cancer was locally advanced. |
| Robotic surgery is proven to be better than radiotherapy for locally advanced disease. | No. There is currently no definitive randomised evidence showing that one approach is superior for every patient. |
Key Takeaways
- Locally advanced prostate cancer does not automatically mean surgery is impossible.
- Robotic radical prostatectomy may be considered in carefully selected patients, particularly when there is no distant metastatic disease.
- MRI and PSMA PET/CT help your specialist understand how far the cancer has spread and whether surgery may be appropriate.
- Surgery may be part of a multimodal treatment plan, so radiotherapy or hormone treatment may still be needed depending on your PSA and final pathology.
- Your treatment choice should consider your cancer stage, Grade Group, lymph-node findings, overall health and the potential side effects of surgery compared with radiotherapy-based treatment.
Frequently Asked Questions
1. Can you have robotic prostate surgery for locally advanced prostate cancer?
Yes, selected men with locally advanced prostate cancer may be suitable for robotic radical prostatectomy. Your scans, cancer stage, overall health and whether the cancer can be safely removed will all influence the decision.
2. What does locally advanced prostate cancer mean?
Locally advanced prostate cancer means the cancer has grown beyond the prostate but has not spread to distant parts of your body. It commonly includes T3 and T4 disease.
3. Is robotic surgery suitable for everyone with locally advanced prostate cancer?
No. Your surgeon will consider the extent and location of your cancer, whether there is evidence of distant spread and your general fitness for major surgery. Radiotherapy with hormone treatment may be more appropriate for some men.
4. Why are MRI and PSMA PET/CT important before surgery?
MRI can show how close your cancer is to the prostate capsule, seminal vesicles and nearby nerves. A PSMA PET/CT can help look for cancer in lymph nodes, bones or other areas of your body.
5. Can you have nerve-sparing surgery with locally advanced prostate cancer?
Possibly, if your cancer is safely away from the nerves responsible for erections. If the tumour is close to these nerves, your surgeon may need to remove more tissue to reduce the risk of leaving cancer behind.
6. Will you need lymph nodes removed during robotic prostate surgery?
You may need pelvic lymph-node dissection if there is a meaningful risk of lymph-node involvement. If lymph-node surgery is performed, current European guidance recommends an extended dissection because it provides more accurate pathological staging.
7. Will you need radiotherapy after robotic prostate surgery?
Not necessarily. Your need for radiotherapy will depend on your PSA, surgical margins, final pathology, lymph-node results and other risk factors after surgery.
8. Will you need hormone treatment after robotic prostate surgery?
Hormone treatment is not automatically required after robotic prostatectomy. It may be considered particularly if lymph nodes contain cancer, your PSA remains persistently detectable or rising, or hormone therapy is being combined with postoperative radiotherapy. Your pathology and PSA results will guide the decision.
9. What happens to your PSA after robotic prostate surgery?
Your PSA should normally fall to a very low or undetectable level after your prostate is removed. A persistent or subsequently rising PSA may indicate that further assessment or treatment is needed.
10. Is robotic surgery better than radiotherapy for locally advanced prostate cancer?
There is no single treatment that is best for every man with locally advanced prostate cancer. Your specialist will compare robotic surgery with radiotherapy and hormone treatment based on your cancer characteristics, overall health and preferences.
Final Thoughts: Choosing the Right Treatment for Locally Advanced Prostate Cancer
Being diagnosed with locally advanced prostate cancer does not necessarily mean surgery is no longer an option. For carefully selected men, robotic prostatectomy can form part of a wider treatment plan, but your cancer stage, MRI and PSMA PET/CT findings, overall health and treatment goals all need to be considered.
If you are considering robotic prostate surgery in London, discussing your case with an experienced specialist can help you understand whether surgery may be appropriate and whether you may need additional treatment afterwards. You can contact our team to talk through your options and arrange a consultation tailored to your individual needs.
References:
- European Association of Urology (2026) EAU Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem, The Netherlands. Available at: https://uroweb.org/guidelines/prostate-cancer
- National Institute for Health and Care Excellence (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Hofman, M.S. et al. (2020) ‘Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study’, The Lancet, 395(10231), pp. 1208–1216. Available at: https://pubmed.ncbi.nlm.nih.gov/32209449/
- Attard, G. et al. (2022) ‘Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol’, The Lancet, 399(10323), pp. 447–460. Available at: https://pubmed.ncbi.nlm.nih.gov/34953525/
- Vale, C.L. et al. (2020) ‘Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data’, The Lancet, 396(10260), pp. 1422–1431. Available at: https://pubmed.ncbi.nlm.nih.gov/33002431/